Related Experiment Videos
Fludarabine therapy in Waldenström's macroglobulinemia
R Thalhammer-Scherrer1, K Geissler, I Schwarzinger
1Department of Medicine I, University of Vienna, Austria.
Annals of Hematology
|December 2, 2000
Summary
Fludarabine effectively treats Waldenström's macroglobulinemia in previously untreated patients, significantly reducing IgM levels and improving anemia. The treatment is well-tolerated with sustained responses in most patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Waldenström's macroglobulinemia is a rare B-cell lymphoproliferative disorder.
- Effective treatment options for previously untreated or minimally pretreated patients are crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerability of fludarabine in patients with Waldenström's macroglobulinemia.
Main Methods:
- Seven patients (six untreated, one minimally pretreated) received fludarabine (25 mg/m2/day for 5 days every 4 weeks).
- Treatment outcomes including IgM levels, hemoglobin, lymphocyte count, and beta2 microglobulin were monitored.
Main Results:
- Six of seven patients achieved marked reduction in IgM levels (median 6,140 to 1,220 mg/dl) and hemoglobin normalization (median 10.8 to 12.3 g/dl).
- Responses were sustained in six patients for 20.8-55.2 months; fludarabine was well-tolerated with minimal side effects.
Conclusions:
- Fludarabine demonstrates significant efficacy in treating Waldenström's macroglobulinemia.
- It offers a well-tolerated and effective therapeutic option for patients with this hematologic malignancy.